Cardiac Remodelling in the Era of the Recommended Four Pillars Heart Failure Medical Therapy
Open Access
- 26 November 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (2) , 1029-1044
Abstract
Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV). Guideline recommended medical therapy for HF, including angiotensin-converting enzyme inhibitors/angiotensin receptors II blockers/angiotensin receptor blocker-neprilysin inhibitors (ACE-I/ARB/ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRA) and sodium-glucose transport protein 2 inhibitors (SGLT2i), have shown to improve morbidity and mortality in patients with HFrEF. By targeting multiple pathophysiological pathways, foundational HF therapies are supposed to drive their beneficial clinical effects by a direct myocardial effect. Simultaneous initiation of guideline directed medical therapy (GDMT) through a synergistic effect promotes a ‘reverse remodelling’, leading to a full or partial recovered structure and function by enhancing systemic neurohumoral regulation and energy metabolism, reducing cardiomyocyte apoptosis, lowering oxidative stress and inflammation and adverse extracellular matrix deposition. The aim of this review is to describe how these classes of drugs can drive reverse remodelling in the LV, LA and RV and improve prognosis in patients with HFrEF.Keywords
This publication has 141 references indexed in Scilit:
- The Prognostic Value of Serial Troponin Measurements in Patients Admitted for COVID-19ESC Heart Failure, 2021
- Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection FractionJAMA Cardiology, 2021
- The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA‐HF studyDiabetes/Metabolism Research and Reviews, 2020
- Sacubitril/Valsartan in Patients with Heart Failure with Reduced Ejection Fraction with End-Stage of Renal DiseaseESC Heart Failure, 2020
- Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection FractionJAMA, 2019
- Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection FractionJAMA, 2019
- Incremental Benefit of Drug Therapies for Chronic Heart Failure with Reduced Ejection Fraction: A Network Meta-AnalysisEuropean Journal of Heart Failure, 2018
- Baseline Characteristics and Treatment of Patients in Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF)European Journal of Heart Failure, 2014
- Different prognostic significance of right and left ventricular diastolic dysfunction in heart failureClinical Cardiology, 1999
- Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart FailureJAMA, 1995